Results 271 to 280 of about 61,821 (357)

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease. [PDF]

Mol Ther Nucleic Acids
Woffindale C, Riera NG, Wood MJA, Varela MA.   +3 more
europepmc   +1 more source

Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation

Chunxiao Xu, Xueyuan Zhou, Lindsay Webb, Sireesha Yalavarthi, Wenxin Zheng, Somdutta Saha, Rene Schweickhardt, Maria Soloviev, Molly H. Jenkins, Susanne Brandstetter, Natalya Belousova, Marat Alimzhanov, Brian Rabinovich, Amit M. Deshpande, Neil Brewis, Laura Helming   +15 more
openalex   +1 more source

Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Vascular normalization, one promising anti‐angiogenic strategy, has the potential to enhance vascular perfusion and elevate the infiltration of immune cells into tumors by rectifying aberrant tumor blood vessels. This results in the enhancement of immunotherapy.
Yu Tang, Yuyan Ding, LiPing Wang, Yujiao Yang, Youwei Han, Peng Zhou, Huiheng Qu, Kaiyuan Deng, Jiazeng Xia   +8 more
wiley   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Differences in Perspectives and Policies Regarding End‐of‐Life Care Between Hematologists and Gastroenterologists

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Patients with hematologic malignancies often receive aggressive treatment until the terminal phase and transition to end‐of‐life (EOL) care less frequently than those with solid tumors. A 2015 survey compared hematologists' and solid tumor‐oncologists' attitudes toward EOL care, revealing differences.
Takuya Matsunaga, Kazuyuki Murase, Shiro Hinotsu, Kohichi Takada, Takanori Teshima, Ken Sato, Yasuhiro Nagaoka, Takayuki Machino, Yusuke Sugama, Masayoshi Kobune, Kunihiko Ishitani   +10 more
wiley   +1 more source

Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions. [PDF]

Sci Rep
Ingavat N, Kok YJ, Dzulkiflie N, Min LJ, Xinhui W, Low KN, But KP, Anajao A, Ping LH, Ong HK, Mahfut FB, Yang Y, Bi X, Zhang W.   +13 more
europepmc   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. [PDF]

J Immunother Cancer
Nan L, Chen L, Huang W, Peng S, Wang C, Liao H, Wang Y, Cui Z, Lv Y, Wang X, Luo Y, Tsun A, Miao X, Zhang J.   +13 more
europepmc   +1 more source

Socioeconomic Status and Access to Treatment in Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Purpose Large B‐cell lymphoma (LBCL) is the most common lymphoma subtype, with diffuse LBCL (DLBCL) accounting for 30%–40% of new lymphoma cases. The International Prognostic Index (IPI) is widely used for prognostic assessment in DLBCL.
Kuitunen Joonas, Marin Katja, Tokola Susanna, Pollari Marjukka, Jyrkkiö Sirkku, Suominen Minna, Partanen Anu, Vuolukka Kristiina, Sunela Kaisa, Rönkä Aino, Aromaa‐Häyhä Annikki, Klaavuniemi Tuula, Hakalahti Anna, E. L. Kuusisto Milla, Kuitunen Hanne, Kuittinen Outi   +15 more
wiley   +1 more source